ALK and neuroblastoma: Kunnimalaiyaan et al. (2018) tested LY2090314 in a panel of NB cell lines with different genetic backgrounds: SH-SY-5Y (non-amplified MYCN or single-copy, wild-type TP53, F1174L ALK mutation), NGP (1p alteration, MYCN-amplified, wild-type ALK, TP53 mutated, MDM2-amplified) and SK-N-AS (1p deletion, MYCN single-copy, H168R TP53 mutation, wild-type ALK), and found that this GSK-3 inhibitor at nanomolar range promoted growth inhibition in a time- and dose-dependent manner irrespective of the cell line markers.